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Summary
The chromatin High Mobility Group protein 1 (HMGB1)1 is a very abundant
and conserved protein that is structured in two HMG-box domains plus a highly
acidic C-terminal domain. From the ability to bind DNA unspecifically and to
interact with various proteins, several functions in DNA-related processes have
been assigned to HMGB1. Nevertheless, its functional role remains the subject of
controversy. Using a phage display approach we showed that HMGB1 can
recognize several peptide motifs. A computer search of the protein databases
found peptide homologies with proteins already known to interact with HMGB1,
like p53, and allowed us to identify new potential candidates. Among them, some
transcriptional activators like heterogeneous nuclear ribonucleoprotein K (hnRNP
K), repressors like Methyl-CpG binding protein 2 (MeCP2), and co-repressors like
the Retinoblastoma susceptibility protein (pRb), and Groucho-related gene
proteins 1 (Grg1) and 5 (Grg5) can be found. A detailed analysis of the interaction
of Grg1 with HMGB1 confirmed that the binding region contained the sequence
homologous to one of the peptides identified. 
Our results lead us to propose that HMGB1 could play a central role in the
stabilization and/or assembly of several multifunctional complexes through
protein-protein interactions.
 
Introduction
In the eukaryotic cell nucleus of all vertebrate cell types HMGB1 (formerly
named HMG1, see (1) for a revised nomenclature) is one of the most abundant
non-histone proteins. HMGB1 is essential since knock-out mice die 24 hours
after birth (2). HMGB1 is highly conserved specially in mammals and to a lesser
extent all through the animal kingdom. HMGB1 is structured into three domains:
two basic HMG-boxes (HMG-domains A and B) and a highly acidic C-terminal
domain that confer an overall dipolar appearance to this protein (see (3-5) for
reviews). Each of the HMG-boxes is formed by two short and one long α-helix
that upon folding produce an L- or V-shaped three dimensional domain structure
(6-8). Whereas the acidic C-terminal domain is presumably involved in the
modulation of HMGB1 activity, the HMG-box domains allow the protein to bind to
linear DNA with moderate affinity and to highly structured (3- and 4-way junction
DNA, cruciform DNA) or distorted DNA (bent or kink DNA, bulged DNA, cisplatin-
modified DNA) with higher affinity but always without sequence specificity. The
concave surface of the L- or V-shaped HMG-box domain contacts the DNA in
the minor groove in two slightly different ways introducing important modifications
in the structure of DNA, in particular a strong bend (reviewed in (5)). Presumably, 
these features will be of relevance for the biological functions in which HMGB1
has been involved (DNA repair, recombination, replication, and transcription).
The activity of HMGB1 is not solely mediated by its ability to bind to DNA.
Indeed, HMGB1 and the related HMGB2 protein can interact through their HMG-
box domains with a broad range of proteins ranging from nuclear cell proteins to
viral proteins. Interactions of HMGB1 have been described with the
Recombination Activation Gene protein RAG1 (9), several transcription factors
including the cellular tumor suppressor p53 (10), the octamer transcription factors
Oct1, Oct2, Oct4 and Oct6 (11,12), some homeotic HOX proteins (13), the steroid
receptors (progesterone PR, glucocorticoid GR, estrogen ER, and androgen AR)
(14,15), the general initiation factor human TATA-binding protein (hTBP) (16-18),
and the viral replication proteins Rep78 and Rep68 (19). The consequences of
these interactions are multiple. HMGB1 in general increases the DNA binding
affinity of those factors and depending on the context and the assay conditions
HMGB1 has shown to have a positive or a negative effect on transcription (14-
17,20). In the case of RAG1 and Rep68/78 HMGB1 enhances the rate of
 
sequence-specific DNA cleavage reaction (19,21). Interestingly, HMGB1 can also
stimulate the ATPase activity of Rep78 (19). 
The two HMG-box domains of HMGB1 appear to have a similar but not
identical behaviour with respect to their protein interacting features. Thus, HMG-
box A is the one important for binding to hTBP and p53 whereas the binding to Oct
factors, HOX factors, and hormone receptors can take place through boxes A or B
(11,13,17,22). However, the interaction with RAG requires both HMG-box
domains (9). 
To date, neither the HMG-box surface that is involved in the interaction
with other proteins nor the amino acids of HMGB1 required are known. On the
other hand, sequence analysis of the factors interacting with HMGB1 does not
highlight any apparent homology or similarity among them. For instance, the
interaction with RAG1, Oct and Hox factors occurs at the homeodomain. In the
case of hTBP it is the H2’ α-helix of the core and with Rep78 two different regions
are recognized. From these data, no consensus can be defined.
The fast progress of genomics and proteomics has made obvious that an
important focus in understanding biological processes is to characterize how
proteins interact in macromolecular complexes. Attempts to define general rules
for predicting specific recognition between proteins have been unsuccessful since
each protein-protein interaction has its own properties. Nevertheless, some
indications are emerging. The development of powerful tools has allowed to
demonstrate that one type of recognition involves asymmetric interactions that
occur between a particular domain and a short region, often less than 10 amino
acids in length, within the other protein. A recent review (23) recapitulated several
examples of protein domains involved in these kinds of interactions like SH3 (Src
homology 3), phosphotyrosine-binding WW, EH (Eps15 homology), PDZ modules
(PSD-95/dlg/ZO1), as well as pRb, and the estrogen receptors (ER). Some of
them, as for the ER, could interact in several modes with different peptides, in a
way depending on the ligand bound. 
In the present study we have explored the molecular recognition properties
of HMGB1 by ligand selection from a large library of heptapeptides displayed on
phages. Our results do not give support to a unique strong consensus sequence
but a few different kinds of peptides. Blast search allowed us to predict some new
proteins that may interact with HMGB1. We have tested and confirmed the
interactions with some of them and showed that HMGB1 can interact not only with
transcriptional activators but also with repressors and co-repressors. Taken
 
together the data suggest a complex network of protein-protein interactions that
will be discussed in order to understand the biological function(s) of HMGB1.
Experimental procedures
Expression and purification of recombinant HMGB1-box A, -boxB, and full-length
HMGB1
The plasmids pT7-HMGB1bA, pT7-HMGB1bB, and pET14b-HMGB1
used for the expression of rat HMGB1 box A, box B, and full-length HMGB1
respectively, have already been described. The procedure used for the expression
and purification of the three recombinant proteins was as described before (17).
Native calf thymus HMGB1 was purified as described before (24).
Peptide phage display analysis with HMGB1 boxes A and B
A phage display heptapeptide library kit (New England Biolabs, Beverly,
Ma) was used to screen for peptides binding to HMGB1-box domains A and B.
The kit contained a random combinatorial collection of heptapeptides fused via a
flexible linker sequence to the N-terminus of protein pIII of bacteriophage M13.
Each phage expressed at the tip of the cover 3 to 5 copies of the unique peptide it
encoded. The library complexity contained all the possible combinations of the 20
natural amino acids taken as 7-mer sequences. For the phage biopanning
process, we followed the kit instructions as indicated by the manufacturer. Four
independent experiments were run in which 30-40µg HMGB1 box A or B were
immobilized overnight at 4°C on 96-wells microtiter plates (Costar 3690). Wells
were then blocked for 1 h at 4°C with TBS-0.1% Tween 20 and 2x1011 plaque
forming units (pfu) of the phage library were added per well and incubated for an
additional hour at room temperature. Wells were washed ten times with TBS-
0.1% Tween 20 for the first round. For the subsequent rounds washing used TBS-
0.5% Tween 20 to increase stringency. Finally, phages were either eluted at room
temperature by incubation with 0.2 M glycine-HCl, pH 2.2 for 10 min or affinity
eluted by incubation for 1 h with 30-40µg of the respective HMGB1 box A or B.
Phage amplification, titration, and purification were carried out according to the
manufacturer protocol. Automatic phage DNA sequencing used the -96gIII primer
(5’CCCCTCATAGTTAGCGTAACG3’) and was performed by the "Serveis
Científico-Tècnics" of the "Universitat de Barcelona". 
The search for homologies in the data banks with the sequences selected
 
in the phage display experiments was performed using the Blast (Basic Local
Alignment Search Tool) program (NCBI, National Center for Biotechnology
Information, USA) (25). The alignments were obtained using the MultAlin program
(Multiple Sequence Alignment, INRA, Institut National de Recherche
Agronomique, Toulouse, France) (26).
GST-fusion constructions and protein purification
All GST-constructs were prepared using the pGEX-4T3 plasmid
(Amersham Pharmacia Biotech). 
The twelve peptides selected to be further analyzed as GST fusions were
amplified from the phages by using PCR with the following primers 5’
TGGTACCTTTGAATTCTCACTC 3’ and 5’ TCAACAGTGTCGACCGAACC 3’
which introduced EcoRI and SalI sites, respectively (underlined). The PCR
products were inserted between these sites in the pGEX-4T3 plasmid.
pGEX-Grg1 and pGEX-Grg5 were constructed by inserting the NaeI-XhoI 
fragments obtained from the pBS-Grg1 and pBS-Grg5 (kindly provided by Dr. C.
Lobe) into pGEX-4T3 digested with SmaI and XhoI. 
pGEX-Grg Q-GP-CcN was produced by inserting a NaeI/SmaI fragment
from pBS-Grg1 into SmaI site of pGEX vector.
pGEX-Grg SP-WD was generated by inserting a SmaI/XhoI fragment of
pBS-Grg1 into the same sites of the pGEX vector.
pGEX-Grg Q was obtained by digesting pGEX-Grg1 with Bpu1102I and
 XhoI, made blunt and self-ligated. 
pGEX-Grg GP-CcN was prepared by digestion of pGEX-Grg1 Q-GP-
CcN with BamHI and Bpu1102I, made blunt and self-ligated.
pGEX-Grg ∆GP-CcN was obtained by inserting a BamHI-XhoI fragment
obtained by PCR from the pGEX-Grg1 construct by using the primers 5’
TTCAGCCTCCTGGATCCCCG 3’ and 5’ GTTTTCTCGAGGTGAGTGTG 3’
(restriction sites underlined) into pGEX 4T3 digested with the same enzymes.
pGEX-Grg SP was generated by inserting a SmaI-XhoI fragment obtained
as above by PCR with primers 5’ ACTCACCCCGGGAAAACG 3’ and 5’
GTTGATCTCTCGAGCATGTCG 3’ into pGEX 4T3 digested with the same
enzymes.
All constructions were verified by manual or automated DNA sequencing. 
pGEX-MeCP2 (207-492) was obtained from Dr. A. Bird. pGEX-KG-hn
RNP K was a gift of Drs. S.K. Jong and J.H. Kim. pGEX-pRb (379-928) and
 
pGEX-p53 were obtained from Dr. M.A. Martínez-Balbás.
All the GST fusions were expressed in E. coli BL21(DE3) and purified
according to standard methods as suggested by the manufacturer (Amersham
Pharmacia Biotech).
Far-Western analysis and Western blotting
GST-peptide fusions were separated by SDS-PAGE and electroblotted in
transfer buffer (25 mM Tris, 40 mM Glycin, 0.05% SDS, 20% methanol) to
nitrocellulose membranes (Optitran BA-85, Schleicher&Schuell). After blocking in
PBST (PBS-0.1% Tween20) containing 5% non-fat dry milk for 1-2 h at room
temperature, membranes were incubated overnight in 10 mL of D buffer without
glycerol (20 mM HEPES, pH7.9, 0.2 mM EDTA, 100 mM NaCl, 0.5 mM DTT, 0.1
mM PMSF) containing 10-to-20 µg of either HMGB1 or its derivatives HMGB1
box A or B. After several washes in PBST membranes were incubated with a
primary chicken anti-HMGB1 antibody raised in our lab against recombinant
HMGB1 deleted of the C-ter domain, subsequently with a secondary anti-chicken
IgY-HRP antibody (Jackson laboratories, USA) and detected using ECL reagents.
Pull-down assays
Glutathione-Sepharose beads (Amersham Pharmacia Biotech) were
loaded with the different GST-fusion proteins as suggested by the manufacturer
and washed 5 times with 450 µL of D buffer containing 20% glycerol. Then, they
were incubated with HMGB1 box A or B for 1 h at 4°C in the same buffer and
 washed 6 times more with the same buffer. Beads were finally boiled in protein
 loading buffer, proteins were separated by SDS-PAGE and detected by Western
blotting with specific antibodies.
Results
Preferential interaction of HMGB1-box domains A and B with some peptides
In an attempt to identify targets that could be potentially recognized by
HMGB1, and since other general approaches like yeast two-hybrid analysis were
not possible  (likely due to toxic effects of the expression of HMGB1-boxes in
yeast, results not shown) a peptide library screening approach was carried out. A
highly complex library containing the whole collection of natural heptapeptide
sequences displayed on phage M13 was used. Four rounds of selection were
 
carried out for each of the four independent experiments that were performed
using highly purified recombinant HMGB1 boxes A or B as bait proteins. During
the biopanning process stringency was increased by using higher detergent
concentrations in the washing buffer. Bound phages were recovered by either a
non-specific acid-elution (exp. 1) or by affinity competition using HMGB1-boxes
A or B free in solution (exps. 2-4). Several peptides were selected as potentially
interacting with HMGB1 with some specificity (Table I). From those results, it
became clear from their sequences that they were not related to a single strong
consensus sequence, suggesting that either the interactions between HMGB1 and
the peptides were weak or that HMGB1 boxes could interact with several
unrelated motifs. We noted that frequencies of appearance of some amino acids in
the selected peptides clearly deviated from the random theoretical level indicating
that the selection process was successful. That is, if interactions of HMGB1 were
specific they should be independent of the particular growth features of the
phages,  their statistics should clearly differ from those of the unselected phages
in the biopanning assays and be due to their ligand-binding requirements. For
example, positively and negatively charged amino acids usually presented
frequencies lower than expected in the selected peptides suggesting that the
interactions did not mainly rely on electrostatic forces despite the highly basic
character of the HMGB1 boxes. Also, a high rate of aromatic residues was
observed, in particular a high level of tryptophan in experiment number 4, which
contrasts with the observation that this amino acid tends to decrease naturally
without selection. A remarkable level of proline was also obtained in experiment
number 3. Hydrophylic amino acids which tend to be involved in hydrogen-bond
recognition, showed some decrease as well. These data indicated that selection
had in fact occurred in the presence of the HMGB1 boxes although no clear-cut
consensus could be easily drawn. 
Despite sequences selected were very variable as shown in Table I, the
appearance of several copies of the same peptide in each experiment indicated a
high enrichment and specificity in the screening. Note also that some peptides
(e.g. HWGMWSY, HAIYPRH) were selected in independent experiments with both
HMGB1 domains. Despite this variability in the peptide sequences it was also
clear that amino acid distribution in the peptides was not at random (Table I).
Thus, peptides could be grouped at least in two classes: some rich in proline and
some others rich in tryptophan. Two peptides enriched in tryptophan, HWGMWSY
and HSWLWWP, accounted for 50% of the clones in experiment 4 and
 
HWGMWSY appeared also in experiments 1 and 2. A minimal consensus WxxW
motif could be a potential site for interaction. In the case of proline-enriched
peptides it was more difficult to define a consensus given the diversity of these
sequences.
Because of the high complexity in the peptide sequences retrieved in the
phage display experiments we were concerned about the potential existence of
false positives in the selected set of peptides. As a second approach to confirm
the bona fide association of HMGB1 with those peptides, we perfomed in vitro 
assays in which peptide sequences were fused to GST. The peptides used were
twelve among those selected with HMGB1 boxes A and B and were
representative of the different kinds of peptides obtained. They were fused to the
C-terminus of GST to facilitate their expression and purification in E. coli. As a
control a GST with an extended, unrelated and never selected peptide was
included (GST-KG). Since direct GST pull-down assays did not work likely
because of steric hindrance of the GST moeity to the very small peptide (not
shown), Far-Western experiments were performed (Fig. 1). In contrast to the
negative control, all the other peptides showed interaction with HMGB1 box B (Fig.
1B). The relative intensity of each band varied from experiment to experiment
indicating that the results were not quantitative. Nevertheless, these interactions
were always detectable whereas interaction with the control was never detected
(Fig1B, lane GST-KG). Moreover, the same assays were also done using either
HMGB1 box A or HMGB1 full-length and results were the same (not shown). 
We noted that none of the peptides selected was represented in the
sequence of HMGB1. Since HMGB1 can only very inefficiently interact with itself
forming a homodimer (27) and HMG-box domains do not interact with each other
inside the HMGB1 molecule (28) this was also suggesting that peptides selected
were representative of reasonable rather than very weak interactions.
Discovery of new partners for HMGB1
Once our results were confirmed it became interesting to make a survey in
order to look for proteins containing regions of homology to the peptides selected
in the phage display assay. This point was addressed by searching the available
databases with the Blast program for nuclear proteins. HWGMWSY was a peptide
that generated interesting candidates and among them appeared ER, a factor
previously identified to interact with HMGB1 (15). We noted a potential WxxW
consensus motif (Table IIB) for the factors belonging to this group. These factors
 
were not studied in detail because in comparison another peptide, LPLTPLP,
generated the most interesting homologies and allowed the identification of a new
set of nuclear proteins that could potentially interact with HMGB1. These putative
factors were summarized in Table IIA. Once again, two other factors - p53 and
PR - already described to interact with HMGB1 appeared (10,14) and
interestingly, the region homologous to our peptide in p53 was highly conserved in
mammals. Remarkably, all the proteins listed presented a potential PxxPxP
consensus motif, and among them components for many transcription factor
complexes can be found. In this list we had only included the proteins containing
the sequence motifs homologous to the peptide that were conserved among
mammalian species. Note that in some cases two conserved motifs could be
found (e.g. Grg1, p53). Also, the two orientations of the motif were considered
because similar proline-rich motifs were reported to be recognized by SH3
domains independently of their orientation ((29) and references therein). 
To confirm that HMGB1 could physically interact with the surveyed proteins
we used a pull-down approach employing GST-p53 as a positive control and
some other proteins fused to GST that were selected as representative of the
several classes described above: the RNA binding protein and positive regulator
hnRNP K, the negative regulator MeCP2, and co-repressors pRb, Grg1 and Grg5.
Since HMGB1 is a protein that presents many posttranslational modifications - at
least including acetylation, ADP-ribosylation and methylation (reviewed in (30)) -
we have taken this fact into account and have analyzed in parallel the interaction
with recombinant and native calf thymus purified HMGB1 (i.e. presenting many
posttranslational modifications, not shown). Fig. 2 shows that HMGB1 can
effectively interact with all the proteins tested with some notable differences
between the recombinant and the purified forms. Whereas either recombinant or
purified HMGB1 interacted with Grg1 to a similar extent, recombinant HMGB1
showed some preference for Grg5, p53, hnRNP K, and pRb. Purified HMGB1, in
contrast, interacted with MeCP2 more efficiently than recombinant HMGB1.
Neither recombinant nor purified HMGB1 could interact with  GST. We wanted to
emphasize, however, that since those results were semiquantitative only large
differences should be taken into consideration. Thus, it was tempting to suggest
that whereas posttranslational modification did not seem to have a major effect on
HMGB1 interaction with some of them (mainly Grg1, but also Grg5 to some
extent) it looks like negatively affecting the interaction with some others (especially
pRb and p53) and in one case being slightly preferred (MeCP2). In this assay the
 
efficiency of the interaction was dependent on the fusion protein. Preliminary data
obtained using recombinant HMG-boxes A and B indicated the same results (not
shown).
Mapping of the interacting regions on Grg1
We further studied the potential of the PxxPxP motif by using Grg1 as a
model target. Grg1 is structured in five domains each of them having a particular
function (Fig. 3A). A highly conserved N-ter glutamine-rich domain (Q) is involved
in protein oligomerization, a C-ter WD-repeat domain is used for interaction with
other proteins, and a central domain encompassing the CcN motif allows the
nuclear localization of Grg1. The two other domains, GP and SP, are poorly
conserved and may play a direct role in repression of transcription (31). By using
different deletions of Grg1 the involvement of the PxxPxP motif in the interaction
with HMGB1 was tested (Fig. 3A). As shown in Fig. 3B splitting of Grg1 molecule
in two moeities, N- and C-terminal, showed that HMGB1 was able to interact with
both, the one containing domains Q-GP-CcN (lane 4) and the other containing
domains SP-WD (lane 8) respectively. 
The binding site on the N-terminal moeity was located at the N-terminal
region of the GP domain since deletion encompassing residues 131-to-155 (Fig.
3B, compare lanes 6, and 7, GST-GP-CcN and GST-∆GP-CcN, respectively)
completely abolished the interaction. Additionally, the Q domain clearly showed
that it could not interact with HMGB1 either (lane 5). The sequence that upon
deletion abolished binding of HMGB1 on this side of the protein precisely
corresponded to the region of homology to the LPLTPLP peptide (Fig. 3C,
shadowed). Note that in the closely related Grg5 factor this region is also present
and is likely used for the interaction with HMGB1 as well (Fig. 2).
The site of interaction in the C-terminal moeity is likely located at the SP
domain since deletion of WD domain does not abolish it. Nevertheless, the
existence of still another site on the WD domain cannot be rouled out. A careful
examination of the amino acid sequence of the SP domain revealed another
region of weaker homology (vPfpPmP) to the LPLTPLP peptide (Fig. 3D). In this
case, this site is absent in the related Grg5 factor. 
Discussion
On the HMGB1 side
 
HMGB1 was first isolated almost thirty years ago and since then much
effort has been put to characterize this protein and find its functional role (30). The
latter point has shown to be difficult because of controversial results and it is still a
matter of discussion. Since HMGB1 does not present any enzymatical activity on
its own or any sequence specific DNA or RNA binding, it is clear that whatever the
functions in which it could be involved it would require the assistance of other
factors, likely proteins. Several reports have clearly shown that HMGB1 interacts
with a set of different factors that present very little, if any, sequence or structure in
common. The question of how HMGB1 can recognize its partners is the one we
have addressed here.
So far, the rules that govern the interactions between two given proteins are
fairly unknown and in any case interactions are impossible to predict. An
hypothesis to reconcile all the data on HMGB1 interactions could be that the
interaction surface recognized by HMGB1 on these proteins might be very short,
so that only few amino acids would be really important. Eventually, not only one of
such motifs could be recognized by HMGB1. This idea is based on recent findings
showing that many different proteins can recognize motifs as short as four to five
residues long as for example, LxCxE for pRb (32) or WRPY/W for Groucho in 
Drosophila (33).
As an approach that sometimes helped in determining the residues that
might be required for the interactions to take place, the screening of peptide
repertoires has been successfully used by several groups to shed some light on
the mechanisms of ligand recognition of macromolecular complexes. The use of a
peptide phage display approach allowed us to begin understanding some of the
previously reported interactions, to predict for some others and to begin testing
them. In our hands, HMGB1 can recognize several short motifs through the HMG-
boxes. However, the lack of a unique sequence motif or a single consensus
sequence derived from them complicated the interpretation of the results and
clearly suggested that HMGB1 is a protein that does not have a highly preferred
sequence to interact but can establish interactions with many peptides having
rather different sequences. Therefore, no strong enrichment is observed and this
heterogeneity makes difficult the interpretation of the results. As far as we know,
this seems to be a particular behaviour of HMGB1. Some of the peptides were
isolated with both HMG-boxes A and B (HWGMWSY and HAIYPRH) suggesting
that either the recognition with these peptides is due to the three-dimensional
structure of the HMG-box or uses some of the most highly conserved regions
 
between the two domains. The other peptides seem to be different for each HMG-
box. However, the complexity of the patterns obtained suggests that the relative
affinities for the peptides are similar and weak. This may in turn enrich a particular
experiment in a certain set of peptides because of slight changes (in temperature
for instance). But it could also be attributable to the differences in sequence of the
two HMG-boxes since their three-dimensional structures are rather similar (6,8).
On the other hand, taken into account that sequence identity in HMG-boxes A
and B is really high when compared to the corresponding domains in HMGB2 it is
also very likely that many if not all of the peptide motifs will also be recognized by
HMGB2 as well. In fact, the apparent redundancy of HMGB1 and HMGB2 is a
general observation for all of the interactions described so far for these proteins
including Oct factors (11,12), steroid receptors (15), hTBP (our unpublished
results), and RAG1 (9) among others. 
Our results do not discard the highly acidic C-terminal domain as
potentially interacting with other factors. In fact, the C-ter domain is the one
involved in the interaction with histone H1 (34) and with the histone dimer
H2A.H2B as well (24), and recently it has been claimed to interact with the
glutamine-rich N-ter domain of human and Drosophila TBP (35). However, the
highly acidic nature of this domain makes its interactions highly electrostatic and in
general weakly specific. 
New HMGB1-interacting proteins come to light
The use of peptides in our assay is likely limiting the set of potential
partners for interaction with HMGB1 to those that are recognized only by
sequence because little structure can be expected from heptapeptides. Therefore,
it is reasonable to expect some of the interactions previously described not to
appear in this assay. This may be the case, for instance, of the interaction to the
H2’ α-helix of hTBP previously described (17). Moreover, the fact that a particular
protein contains one of the motifs in its sequence does not necessarily imply that
this will be the site used for interaction or that another motif can be used. In
addition, the contribution of peptidic sequences around the motifs identified here
can be determinant, as in some cases have been shown to play a major role either
in modulating or even in affecting the specificity the interactions. Additionally, the
accessibility of the motifs embedded in some protein contexts might be rather
limited. Finally, there is always a potential for HMGB1 to be actively recognized by
the other partner (see below) and then motifs can be completely different.
 
When searching protein databases, a point that must be taken into account
is that the relative representation of the different peptides and motifs  is not
homogeneous. Thus, some peptide motifs produce long lists of proteins, like for
PxxPxP, whereas other motifs do not. Nevertheless, some motifs not studied here
in detail also generated very interesting candidates. For instance, a sequence
closely related to the potential WxxW motif - and in particular to peptide
HWGMWS - can be found in conserved sequences of the α- and β-ER of
mouse, rat and human, of ETS-1 and also in a conserved sequence of the mouse
and human RNA-binding protein nucleolysin TIAR among others (Table IIB).
Remarkably, the interaction with α-ER was previously described. Moreover,  the
proposed HMGB1-binding sequence lies very close to the  Zn-finger of the ER
that interacts with DNA and is clearly accessible in the co-crystal structure
(15,36). These features might help to explain how can HMGB1 stabilize the
interaction of ER with DNA. 
The PxxPxP consensus motif has predicted the most interesting partners
upon Blast search and for that reason has been studied in detail. These include
pRb, MeCP2, hnRNP K, Grg1, Grg5 and p53. Remarkably, p53, which was
previously described to interact with HMGB1, appeared giving credit to this linear
sequence as a potential HMGB1 recognition motif. In fact, all the PxxPxP
containing proteins tested here showed to interact with HMGB1. The reason for
this clear result is likely due to the high proline content of this motif, that difficults
the adoption of a defined secondary structure even if embedded in a protein
sequence. Thus, it is very likely that other proteins containing this motif and listed
in Table IIA will interact with HMGB1 as well. 
HMGB1 was already described to interact with p53 and be a unique
activator of this factor (10). The PxxPxP motif is always found at the N-terminus of
p53 around position 80-90 in the different species and forming part of a proline-
rich domain that negatively affects p53 interaction with DNA (37). The interaction
of HMGB1 at this domain could explain the stimulatory effects observed on DNA
binding and transactivation (10). Since the proline-rich domain is dispensable for
transactivation (38) the role of HMGB1 might be restricted to stabilize the p53-
DNA complex. We must mention, however, that residues 363-to-376 in the basic
domain of p53 have been recently reported to recognize HMG-box A on HMGB1
and that p53 conversely enhanced HMGB1 interaction with cisplatin-modified
DNA (22). In this region of p53 no homology to any of the peptides identified in this
work can be found. This might be in apparent contradiction to the data discussed
 
above but they could be reconciled if there is mutual recognition between p53 and
HMGB1. If so, HMG-box A would be recognized by the C-terminal region of p53
and the proline-rich domain of p53 would be recognized by the HMG-boxes of
HMGB1. Depending on the experimental conditions one or the other interaction
would prevail and be selected. 
This may also be the case of pRb because in addition of having a sequence
showing homology to the PxxPxP motif, the "pocket" region of pRb can recognize
the LxCxE motif in other proteins (32). This motif (as the sequence LFCSE) occurs
to be present in the HMG-box B of both HMGB1 and HMGB2 and is absolutely
conserved in vertebrates. We have not analyzed here in detail whether recognition
is via the LxCxE motif (i.e. pRB recognizes HMGB1) or the PxxPxP motif in pRb
 (i.e. HMGB1 recognizes pRb) and simply described this interaction. Although it is
possible that the interaction may work in both directions we reason that it looks
difficult since the LFCSE sequence is structured into an α-helix facing the
concave side of the L-shaped domain and is partially buried in HMG-box B (6).
The interaction between HMGB1 and Grg1 has been studied in more detail
because of the high homology to the peptide and also because this is the first
interaction of HMGB1 with a co-repressor. In Grg1 two regions of interaction with
HMGB1 have been uncovered. The one corresponding to the GP domain fits
nicely with high homology to the LPLTPLP peptide isolated in the phage display
analysis and very likely accounts for that interaction as predicted. In the second
domain interacting with HMGB1, the SP domain, also a region with the PxxPxP
motif is present albeit homology to the original peptide sequence is weaker. These
results support the PxxPxP motif as a good recognition sequence for HMGB1.
Brantjes et al. have recently described that all Tcf HMG-box transcription factors
interact with Groucho-related co-repressors and even more, all the long members
containing five domains (here represented by Grg1) mediated repression of the
Tcfs, whereas the short member (Grg5) mediated de-repression. All Tcfs are
HMG-box transcription factors but so far the region that interacts with the Grgs
has never included the HMG-box domain. At a difference HMGB1 uses the HMG-
box domains to interact with Grg proteins suggesting that recognition of the
PxxPxP motif is not a feature common to all HMG-box domains. On the other
hand, transcription mediated by AR is inhibited by Grg5 (39). Since the PxxPxP
motif is also present in the AR sequence (Table IIA) and  the interaction of
HMGB1 with AR stabilizes the AR-DNA complex as shown by others, the
interaction of HMGB1 with Grg5 could cooperate by displacing it from AR and
 
helping to relieve inhibition (15). 
MeCP2 is a protein involved in the recognition of methylated DNA at CpG
islands and is closely related to gene silencing (see (40) for a review). The
HMGB1 binding motif is located at the C-terminus of this protein (residues 380-
386) in a region where no other factor has been shown to interact. Therefore, it is
possible that HMGB1 interaction does not interfere the binding of the many factors
known to interact with MeCP2, (among other mSin3A, NcoR and c-Ski) and
remains to be analyzed whether in this case this interaction could also stabilize
MeCP2-DNA complexes as done by HMGB1 in other complexes. 
hnRNP K presents a remarkable variety of protein interactions with some
factors involved in signal transduction, and others involved in several aspects of
gene expression (reviewed in (41,42)). This diversity suggests that hnRNP K
protein may act as a docking platform or as a scaffold protein within multiple
functional modules. Then, HMGB1-hnRNP K interaction may connect two
systems which have a large protein-protein interaction potential to extend their
respective domains of action even further. For example, hnRNP K has shown to
be a transcription activating factor for the c-myc promoter (43,44). Although we
have not been able to establish a direct connection, it is remarkable that c-myc 
mRNA levels in HMGB1 -/- mouse cells are about 5-to-10 fold lower than those
in wt cells (unpublished results).
 We have focus so far on the nuclear environment where HMGB1 is
expected to play a role in gene expression. However, HMGB1 is an extraordinary
protein and besides of being a nuclear protein in most cases it is also true that for
more than ten years HMGB1, under the name of amphoterin was found on the
outer cell membrane of some cell types (45). It is now clear that  HMGB1 could be
actively released outside the cell in response to tumor necrosis factor  and
interleukin 1  (46), and passively by necrosis or cell damage in a variety of cell
types, mainly immature and transformed cells (47).  Release of HMGB1 induces
some pathological processes as a potent late mediator of endotoxin lethality and
inflammation. Many of these phenomena require the interaction of HMGB1 with
the receptor for advanced glycation products (RAGE) (reviewed in (48)).
Examination of the mouse RAGE amino acid sequence shows a region highly
homologous to the LPLTPLP motif in the second Ig-like C2-type domain that is
highly conserved among several species. Similarly, HMGB1 was also shown to
interact with Syndecan-1, a cell surface heparan sulfate-rich proteoglycan (49) in
which sequence a PxxPxP motif can also be found. These and other data suggest
 
that HMGB1 might use the same motifs to interact with cell surface proteins and
with nuclear factors. 
Final considerations
Prior to this work, HMGB1 already had a long list of proteins to which it
interacts. Along with the new candidates reported here it may give the impression
that HMGB1 interacts with almost every protein in the cell. Despite HMGB1 is in
fact a "sticky" protein (48), that is by no means true. For example,  we have been
trying to extend the initial interaction of HMGB1 with human TBP to other factors
of the general transcription machinery and we failed to observe any interaction of
HMGB1 with TFIIA, TFIIB, TFIIF, the CTD of RNA pol II, TFIIE (despite a clear
interaction can be observed with the p56 subunit no interaction at all can be
observed with the native tetramer), and a TBP-related factor among others
(unpublished results), suggesting that the list of factors interacting with HMGB1
may be long but by no means indiscriminate. This particular behaviour makes
difficult to attribute a defined role to HMGB1 in the organism but may explain the
general weakness observed in the HMGB1 knock-out mice that lead them to
death 24 hours after birth (2). HMGB1 seems to have developped a high potential
for protein-protein interaction with multiple partners, always taking part of a
macromolecular complex and either assisting in the assembly or stabilizing the
assembled factors. This feature along with the remarkable abundance of HMGB1
in the nucleus and the many posttranslational modifications that undergoes could
explain its general involvement in nuclear processes and its modulation. 
On one hand, HMGB1 is a protein that can interact with angled DNA on its
own. On the other hand, a general observation is that upon interaction HMGB1
can help stabilizing many proteins previously bound to DNA. These functions may
be compatible but whereas the concave region of the L-shaped HMG-box domain
clearly is the DNA interaction site,  there is no data about the region of the HMG-
box domain involved in the interaction with other protein factors. Some evidence at
the enhanceosome of BHLF-1 suggests that HMGB1 can at the same time
interact with the narrow groove of DNA and with protein factors (50). However,
more detailed work is required to know whether HMGB1 could simultaneously
interact with proteins and DNA, the stoichiometry of the interactions and how its
binding can stabilize protein-DNA complexes. A potential role of co-factor is
emerging for HMGB1 in many different processes.
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Footnote
1The abbreviations used are: HMGB1, High Mobility Group protein 1; pRb,
Retinoblastoma protein; hnRNP K, heterogeneous nuclear ribonucleoprotein K;
MeCP2, Methyl-CpG binding protein 2; Grg1, Groucho-related gene protein 1;
Grg5, Groucho-related gene protein 5; GST, Glutathione S-transferase.
Figure legends
Table I
Amino acid sequences of the heptapeptides bound to HMG-boxes A and B of
HMGB1.
Heptapeptide amino acid sequences deduced from phage sequencing are
recapitulated here for each independent experiment.
a
 Peptides eluted unspecifically by low pH
b
 Peptides eluted by affinity with the same HMG-box used for the biopanning
c Number of peptides sequenced per experiment
The number of clones encoding the same peptide for each experiment is indicated
in brackets. 
Table II
Some potential candidates for interaction with HMGB1.
Blast search results of homology for the heptapeptides LPLTPLP (A) and
HWGMWSY/HSWLWWP (B). The name of the candidate protein is indicated on
the left column, the sequence of homology to the query peptide with indication of
the residue numbers for each case is shown in the middle column, and the
accession number is quoted on the right column.
Figure 1
HMGB1 interacts with twelve different peptide sequences
A. Scheme of the C-terminal amino acid sequences of the twelve GST-peptide
fusions analyzed. Residues boxed in gray correspond to the heptapeptide
sequences. Residues around them correspond to the sequence of pIII protein of
M13 in which they were included. GST-KG was the negative control used for the
 
experiments. 
B. Far-western assay of the twelve GST-peptide fusions described above and
GST-KG as a negative control probed with HMGB1 box B.
Figure 2
HMGB1 interacts with several transcriptional regulators
Pull-down assay of recombinant (r) and purified (p, highly modified) HMGB1 with
GST fusions of p53, pRb, hnRNP K, MeCP2, Grg1 and Grg5 (see Experimental
Procedures for details). GST alone was used as negative control. Lanes
containing 10% of the input material and corresponding to recombinant (Input r)
and purified (Input p) HMGB1 are shown on the left and the right, respectively. In
order to analyze the effect of posttranslational modifications on the interactions of
HMGB1, equal amounts of GST-fusions were used with the two HMGB1
preparations. Recombinant HMGB1 migrates slightly above purified HMGB1
because of the addition of a ~1kD histidine-tag.
Figure 3
Determination of HMGB1 binding sites on Grg1
A. Scheme of the structure of Grg1 in five domains (Q, GP, CcN, Sp, and WD-
repeat) and of the GST fusions used below. The black and white arrows indicate
the positions of the potential HMGB1 binding sites.
B. Mapping of the HMGB1 binding sites on Grg1 by pull-down analysis. GST-
fusions described in A were used to map the interaction of recombinant HMGB1.
Lane 1 shows 10% of the input used for the experiments and lane 2 GST as
negative control. 
C. Alignment of the amino acid sequence homologous to the LPLTPLP and
corresponding to the black arrow.
D.Alignment of the amino acid sequence homologous to the LPLTPLP and
corresponding to the white arrow.
 
Table I
Exp. 1
box Aa
c7
Exp. 2
box Ab
c31
Exp. 3
box Bb
c29
Exp. 4
box Bb
c20
 HWGMWSY  
 NWGMWSY  
 PHWTWVL
 HMSKPVQ
 SSGTHAK
 YNINIRP
 NYTQTVP
 SSPHNHS (6)
 HAIYPRH (6)
 QISFMAN (4)
 TLTTPIL (2)
 HWGMWSY  
 ISIPRTM  
 TPAHNDY  
 FHMGQPF
 APTPVKL
 HMALNxV
 MHSLSYR
 WHWWPxL
 GETRAPL
 VQASNSN
 GNSLRWD
 SAPQILL
 DTDPPGL
 IQSPHFF (8)
 LPLTPLP (7)
 NQDVPLF (2)
 WPKLASH (2)
 SPAHAAK
 ASMSVAI 
 AWLPWAK
 MPNRTAN
 NLPAYTS
 CSSVETH
 GTPTLxS
 VMPWVHK
 YAPRLRS
 APPTRNQ
 HWGMWSY (5)
 HSWLWWP (5)
 LAMPQYE (2)
 KLWVIPQ  
 SHWFWSW  
 HAIYPRH  
 SRPHTSD
 HYWWWPR
 SSSSHPT
 PGAQLTK
 STTLRYF
 
Table II
A   
Putative
Interactors
Motifs of homology
     LPLTPLP
Accession 
number
Grg5  140 LPLTPLP 146 Q06195
Grg1/TL1  141 VPLTPHP 147
 459 VPFPPMP 465 
Q62440
TLE2  160 VPLTPRP 166 NP 062699
p53   76 GPVAPAP 82
  83 APATPWP 89
P02340
hnRNP K  307 LPLPPPP 313 Q60577
MeCP2  380 MPLLPSP 386 NP 034918
pRb  780 RPIHPIP 774 A33718
P107  956 PPLSPFP 962 Q64701
P130 1028 PPLSPYP 1034 Q64700
DP2   19 NPYTPAP 25 Q64163
RelB   75 GPAAPPP 81 Q04863
PR  415 FPLAPAP 421 Q00175
AR  280 LPACPTP 274 P19091
HAIRLESS  179 WPLAPNP 185 Q61645
CDP  913 QPTTPLP 919 P53564
RBP-Jκ  375 APVTPVP 381 P31266
ERF  243 EPLSPFP 249 P70459
IRF2  315 APVTPTP 321 P23906
MNT  511 LPLYPQP 517 O08789
MCMT 1327 LPLFPEP 1333 P13864
RFX1   80 QPATPAP 86 P48377
Sox18  288 NPLSPPP 294 P43680
TTP   69 APLAPRP 75 P22893
Six5  535 LPVGPSP 541 P70178
FREAC 3   65 GPYTPQP 72 CAA11239
TFE3  312 LPVPPNP 318 Q64092
SREBP-1   93 APLSPPP 99 Q9WTN3
TGIF  154 RPVSPKP 160 AAH05724
CTCF  648 QPVAPAP 654 NP 031820
AF-4 1103 SPLSPMP 1109 AAB82427
HNF-3G   26 SPVNPVP 32 CAA52892
C-EBPβ   12 LPLPPPP 18 P17676
TAF250 1640 GPYTPQP 1646 P21675
HES1  187 PPLVPIP 193 P35428
MATH1   29 PPLTPQP 35 P48985
MATH2  258 GPLSPPP 265 P48986
Consensus      XPLTPXP
       VS
       AA
       YP
       IL
       TH
       GY 
        F
        G
        N
        V
        C
 
Table II
B   
Putative
Interactors
Motifs of homology
     HWGMWSY
    HSWLWWP
Accession 
number
ER α  200 HYGVWSC 206 P19785
ER β  160 HYGVWSC 166 O08537
TIAR  309 QWGQWSQ 315 P70318
ETS1   79 DWVMWAV 85 P27577
T2A  123 QWNMWIP 129 Q16514
pRB  67 RAWLTWE 73 P13405
TOP1 203 QKWKWWE 209 BAA00950
ERGB 139 RQWLEWA 145 CAA42055
 



